Ulcerative Colitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Mesoblast Ltd., InDex Pharma

DelveInsight's "Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ulcerative Colitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ulcerative Colitis Market Forecast
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Ulcerative Colitis Market Report:
• The Ulcerative Colitis market size was valued approximately USD 6,900 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, there were 2,223,000 people with Ulcerative Colitis overall in 2022. Throughout the projected period (2023-2032), these cases are anticipated to increase until 2032
• In the 7MM, the United States reported the highest prevalence of Ulcerative Colitis cases in 2022, totaling 1,026,000, or roughly 46% of the 7MM's total cases
• The country with the most cases of Ulcerative Colitis among the EU4 and the UK had 357,000 cases in 2022
• Key Ulcerative Colitis Companies: AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Mesoblast Ltd., InDex Pharmaceuticals, Arena, Protagonist Therapeutics, Palatin Technologies, Inc, Pfizer, Amgen, AbbVie, Landos Biopharma Inc., Mesoblast, Inc., Bristol-Myers Squibb, Abivax S.A., Oppilan Pharma, EA Pharma, Sanofi, Galapagos NV, Immunic AG, Ferring Pharma, and others
• Key Ulcerative Colitis Therapies: Risankizumab (ABBV-066), Mirikizumab (LY3074828), Tremfya (Guselkumab), Remestemcel-L, Corbitolimod, Etrasimod (APD334): , PN-943, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, NX-13, Remestemcel-L, Ozanimod, ABX464, VTX002, AJM300, SAR443122, GLPG3970, IMU-838, Budesonide, and others
• The Ulcerative Colitis epidemiology based on gender analyzed that moderate-to-severe Ulcerative Colitis cases accounts for ~55% of the total cases and the rest of the cases falls under mild category
• The Ulcerative Colitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ulcerative Colitis pipeline products will significantly revolutionize the Ulcerative Colitis market dynamics.

Ulcerative Colitis Overview
Inflammation and ulcers on the inner lining of your large intestine are symptoms of the chronic inflammatory bowel disease (IBD) known as ulcerative colitis.

Get a Free sample for the Ulcerative Colitis Market Report
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ulcerative Colitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ulcerative Colitis Epidemiology Segmentation:
The Ulcerative Colitis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Ulcerative Colitis
• Prevalent Cases of Ulcerative Colitis by severity
• Gender-specific Prevalence of Ulcerative Colitis
• Diagnosed Cases of Episodic and Chronic Ulcerative Colitis

Download the report to understand which factors are driving Ulcerative Colitis epidemiology trends @ Ulcerative Colitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ulcerative Colitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ulcerative Colitis market or expected to get launched during the study period. The analysis covers Ulcerative Colitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ulcerative Colitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ulcerative Colitis Therapies and Key Companies
• Risankizumab (ABBV-066): AbbVie and Boehringer Ingelheim
• Mirikizumab (LY3074828): Eli Lilly and Company
• Tremfya (Guselkumab): Janssen
• Remestemcel-L: Mesoblast Ltd.
• Corbitolimod: InDex Pharmaceuticals
• Etrasimod (APD334): Arena
• PN-943: Protagonist Therapeutics
• PL8177: Palatin Technologies, Inc
• Mirikizumab: Eli Lilly and Company
• Etrasimod: Pfizer
• Efavaleukin alfa: Amgen
• ABBV-668: AbbVie
• NX-13: Landos Biopharma Inc.
• Remestemcel-L: Mesoblast, Inc.
• Ozanimod: Bristol-Myers Squibb
• ABX464: Abivax S.A.
• VTX002: Oppilan Pharma
• AJM300: EA Pharma
• SAR443122: Sanofi
• GLPG3970: Galapagos NV
• IMU-838: Immunic AG
• Budesonide: Ferring Pharma

Discover more about therapies set to grab major Ulcerative Colitis market share @ Ulcerative Colitis Treatment Market
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ulcerative Colitis Market Strengths
• With the market dynamics shifting towards medications with oral ROA, emergence of therapies like BT-11, AJM300, Etrasimod, and SHR0302 will further drive the UC therapeutic market.
• Robust emerging pipelines with novel MOAs with less immunogenicity such as cobitolimod, BBT-401, Omilancor, and others are likely to strengthen the market.

Ulcerative Colitis Market Opportunities
• There lies tremendous potential in the UC landscape for drugs with better clinical profile especially in terms of safety. Safety concerns associated with JAK inhibitors poses a great opportunity for pharmaceutical companies to work on this front and improve the safety profile of upcoming drugs.
• Limited treatment options available in case of relapsed or refractory pool, provides lucrative opportunities in the UC therapeutic space.

Scope of the Ulcerative Colitis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ulcerative Colitis Companies: AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Mesoblast Ltd., InDex Pharmaceuticals, Arena, Protagonist Therapeutics, Palatin Technologies, Inc, Pfizer, Amgen, AbbVie, Landos Biopharma Inc., Mesoblast, Inc., Bristol-Myers Squibb, Abivax S.A., Oppilan Pharma, EA Pharma, Sanofi, Galapagos NV, Immunic AG, Ferring Pharma, and others
• Key Ulcerative Colitis Therapies: Risankizumab (ABBV-066), Mirikizumab (LY3074828), Tremfya (Guselkumab), Remestemcel-L, Corbitolimod, Etrasimod (APD334): , PN-943, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, NX-13, Remestemcel-L, Ozanimod, ABX464, VTX002, AJM300, SAR443122, GLPG3970, IMU-838, Budesonide, and others
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Ulcerative Colitis Unmet Needs, KOL's views, Analyst's views, Ulcerative Colitis Market Access and Reimbursement

To know more about Ulcerative Colitis companies working in the treatment market, visit @ Ulcerative Colitis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Ulcerative Colitis Market Report Introduction
2. Executive Summary for Ulcerative Colitis
3. SWOT analysis of Ulcerative Colitis
4. Ulcerative Colitis Patient Share (%) Overview at a Glance
5. Ulcerative Colitis Market Overview at a Glance
6. Ulcerative Colitis Disease Background and Overview
7. Ulcerative Colitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Ulcerative Colitis
9. Ulcerative Colitis Current Treatment and Medical Practices
10. Ulcerative Colitis Unmet Needs
11. Ulcerative Colitis Emerging Therapies
12. Ulcerative Colitis Market Outlook
13. Country-Wise Ulcerative Colitis Market Analysis (2019-2032)
14. Ulcerative Colitis Market Access and Reimbursement of Therapies
15. Ulcerative Colitis Market Drivers
16. Ulcerative Colitis Market Barriers
17. Ulcerative Colitis Appendix
18. Ulcerative Colitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Ulcerative Colitis Pipeline https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Ulcerative Colitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Ulcerative Colitis market. A detailed picture of the Ulcerative Colitis pipeline landscape is provided, which includes the disease overview and Ulcerative Colitis treatment guidelines.
Ulcerative Colitis Epidemiology
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ulcerative Colitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Ulcerative Colitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.